OneDrug

Pharmacogenetic Screening for Depression Cuts Costs and Boosts Quality of Life, Study Finds

www.sciencedirect.com

Indiana University’s Precision Health Initiative Paves the Way for Sustainable Pharmacogenetics Implementation in Clinical Care

Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned In 2019, Indiana University launched the Precision Health Initiative to enhance the institutional adoption of precision medicine, including pharmacogenetics (PGx) implementation, at university-affili...

New Research Finds Testing for DPYD Variants Alone May Not Prevent All Fluoropyrimidine Toxicities

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD - Genome Medicine Background The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mitigate the risk of severe fluoropyrimidine toxi...

A study evaluated the risk of CYP2C19 phenoconversion, where drug metabolism changes due to drug-drug interactions. Healthy volunteers with different CYP2C19 genotypes were given omeprazole alone and with inhibitors voriconazole and fluvoxamine. Over 80% of participants experienced phenoconversion, with significant differences observed between genotypes. The findings highlight the importance of considering both genetic testing and phenotyping when predicting drug response.

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers To compensate for drug response variability, drug metabolism phenotypes are determined based on the results of genetic testing, and if necessary, drug dosages are adjusted. In some cases, discrepanci...

📢 New study highlights the power of pharmacogenomic testing in treating depression! Patients with personalized treatment plans showed higher remission and response rates, plus fewer side effects. Personalized medicine is making a difference! 🌟

www.sciencedirect.com

📢 Attention Pharmacists and Pharmacy Managers! 📢

We're conducting a crucial survey on the Implementation of Pharmacogenetic Testing in Community Pharmacies Using Point-of-Care Diagnostic Devices. Your valuable insights will help us understand how to effectively bring this cutting-edge technology to your pharmacy.

🧬 Why Participate?

Influence the development of innovative pharmacogenetic testing devices.

Help improve patient care and medication management.

Contribute to the future of personalized medicine in community pharmacies.

🔍 What We Need From You:

Feedback on potential benefits and barriers.

Your vision for integrating pharmacogenetic testing into pharmacy services.

Your definition of a user-friendly testing device.

📋 Take the Survey Here: https://docs.google.com/forms/d/e/1FAIpQLSeRydmob41cORC0ZMHCwChTyPoHPYc8h1aAQIyrHBNe_GT4ZA/viewform

Thank you for your time and insights! Together, we can revolutionize patient care and safety in community pharmacies.

Implementation of Pharmacogenetic Testing in Community Pharmacies Using Point-of-Care Diagnostic Devices Pharmacogenetics is the study of how an individual's genes affect their response to medications. It enables healthcare providers to customize treatment plans based on genetic information, improving drug effectiveness and minimizing side effects for patients. This personalized approach to medication,...

Genetic insights from Tanzania: CYP2B6 and ABCB1 genes impact methadone processing in opioid-addicted patients. Tailoring treatment based on these findings could enhance safety and effectiveness.

BPS Publications The British Journal of Clinical Pharmacology is a leading international clinical pharmacology journal published by the British Pharmacological Society.

🌟 Welcome to the future of healthcare with One Drug! 🌟 Personalized medicine tailored just for you. Revolutionising your treatment with innovative solutions. 💊🧬💉

Did you know that nanotechnology is revolutionizing precision medicine? Discover how these tiny innovations are making a huge impact! 💡

🔬 What is Nanotechnology?
Nanotechnology involves manipulating materials at the molecular or atomic level to create new structures and devices.

Read about the impact of bioinformatics on disease understanding and treatment, emphasizing the need for affordable and efficient biomarker monitoring to enable precision medicine. The article proposes using DNA nanotechnology for this purpose, presenting a method for multiplexed biomarker detection and a novel approach for highly specific protein detection through DNA origami structures.

Read the full article to learn more about these advancements and their potential to transform healthcare.

Aquilina, M. Unlocking precision medicine using DNA nanotechnology. era.ed.ac.uk(2023).doi:https://doi.org/10.7488/era/3819
URL: https://era.ed.ac.uk/handle/1842/41080

A new study on Japanese men with alcohol dependence reveals how specific gene variants affect drinking habits and withdrawal symptoms. Those with ADH1B*1/*1 and ALDH2*1/*1 genotypes showed accelerated development of drinking issues. Flushing response had limited impact on drinking events.

journals.lww.com

Study finds integrating DPYD/UGT1A1 testing in GI cancer care is feasible. Preemptive dose reductions based on genetic variants show promise in reducing severe treatment-related adverse events. Results underscore the importance of personalized medicine in optimizing chemotherapy outcomes.

Implementing DPYD/UGT1A1testing to prevent treatment related adverse events (TRAE) in patients with gastrointestinal (GI) cancer: Results of a pragmatic implementation trial. 10599 Background: Fluoropyrimidines (FP), 5-FU and capecitabine, are standard treatments for many GI cancers. Irinotecan may be used with FPs in both the curative and palliative settings. 30-40% of patients experience severe TRAEs which can lead to treatment interruption and hospitalization. TRAE ri...

Study finds certain genetic variants linked to how patients with familial hypercholesterolemia respond to statins & risk of adverse effects.

journals.lww.com

Implementing preemptive DPYD testing for fluoropyrimidine therapy can save lives!

Implementing preemptive DPYD testing for fluoropyrimidine therapy can save lives!

Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine PURPOSE Several allelic variants of the gene DPYD encoding dihydropyrimidine dehydrogenase (DPD) are associated with impaired metabolism of the systemic fluoropyrimidine fluorouracil (5FU) and its oral prodrug, capecitabine, which elevates the risk for severe toxicity. Following a patient death rela...

A new study investigated how genetic variations influence the response to gemcitabine-based chemotherapy in metastatic pancreatic cancer patients. While certain gene variants showed potential links to treatment response and overall survival, particularly COX-2 polymorphisms impacting survival, genetic factors related to gemcitabine metabolism did not significantly affect treatment efficacy. These findings shed light on personalized cancer therapy approaches.

Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study) Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

New study investigates how genetic variants in CYP3A5 and CYP3A4 impact tacrolimus metabolism in heart transplant patients. Results suggest that combined analysis of these genes could refine tacrolimus dosing for better outcomes post-transplant.

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients - The Pharmacogenomics Journal CYP3A5 genetic variants are associated with tacrolimus metabolism. Controversy remains on whether CYP3A4 increased [*1B (rs2740574), *1 G (rs2242480)] and decreased function [*22 (rs35599367)] genetic variants provide additional information. This retrospective cohort study aims to address whether .....

A study finds a common genetic variation in ACE2 increases the risk of SARS-CoV-2 infection and severe COVID-19. This discovery highlights the importance of genetic factors in COVID-19 susceptibility.

https://journals.lww.com/jpharmacogenetics/fulltext/2021/10000/ace2_polymorphism_and_susceptibility_for.1.aspx?WT.mc_id=HPxADx20100319xMP

New study reveals UK public's strong preference for noninvasive pharmacogenetic testing in primary care! Survey of 1993 individuals shows a clear desire for data sharing between healthcare organizations. Findings emphasize the need for tailored services to optimize uptake and effectiveness.

https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.16058

Implementing proactive DPYD testing for patients receiving fluoropyrimidine-based chemotherapy is crucial for minimizing severe toxicity risks. An opt-out testing approach, driven by automated reminders, achieved a remarkable testing rate of over 90%. With standardized processes and targeted education, allelic variants in 4.1% of patients were identified, allowing for personalized dose adjustments in 96% of cases. This strategy can serve as a model for healthcare institutions aiming to enhance patient safety.

Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine PURPOSE Several allelic variants of the gene DPYD encoding dihydropyrimidine dehydrogenase (DPD) are associated with impaired metabolism of the systemic fluoropyrimidine fluorouracil (5FU) and its oral prodrug, capecitabine, which elevates the risk for severe toxicity. Following a patient death rela...

New study utilizing UK Biobank data confirms substantial impact of CYP2C19 genotype on clopidogrel outcomes, emphasizing the need for genotype-based prescribing in clinical practice.

https://journals.lww.com/jpharmacogenetics/fulltext/2024/04000/pharmacogenetics_at_scale_in_real_world.2.aspx

A clinical study showed higher CYP2D6 activity linked to lower odds of symptom improvement & possibly fewer side effects. Important for SSRI treatment guidelines!

Impact of Cytochrome P450 Genetic Variation on Patient-Reported Symptom Improvement and Side Effects Among Children and Adolescents Treated with Fluoxetine | Journal of Child and Adolescent Psychopharmacology Background: Clinical practice guidelines recommend the use of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), as a first-line pharmacotherapy for major depressive disorder (MDD) and obsessive compulsive disorder (OCD) in children and adolescents. However, response and tolerability to fl...

In a Canadian clinical cohort study, genetic variants in DPYS gene were not found to contribute significantly to chemotherapy-associated severe side effects.

journals.lww.com